Versions :<123456Live
Snapshot 6:Tue, Feb 24, 2026 3:58:10 PM GMT last edited by ArthursSeat22

GPs to Get £3,000 Incentive for Weight Loss Drug Referrals

GPs to Get £3,000 Incentive for Weight Loss Drug Referrals

Is expanding GP access to weight-loss drugs a vital health strategy, an opportunity best seized by pharmacies or a dangerous profit-driven scheme?
GPs to Get £3,000 Incentive for Weight Loss Drug Referrals
Above: A Mounjaro weight-loss jab in Totnes, Devon, on Feb. 20. Image credit: Matthew Horwood/Getty Images

The Spin

This initiative is part of the government's strategy to tackle the burden of obesity on the U.K.'s health services and economy. By encouraging GPs to offer these life-altering medications to the wider public, the government can ensure that those who need this form of treatment, but cannot afford it privately, will receive it with wraparound support.

While the NHS's rollout of weight-loss drugs remains painfully slow, with only a handful of patients treated, placing the burden on overstretched GPs is not the answer. The government should instead consider commissioning pharmacies, which can provide the sustainable weight-loss treatment required more quickly than the sluggish NHS system.

This scheme creates dangerous incentives by paying GPs thousands of pounds to prescribe medications without any long-term safety data. With hundreds already dead and injured as a result of these treatments, it is clear that the government is prioritizing corporate profit over patient safety by pushing this medical quackery.

Metaculus Prediction

There's a 50% chance that the reported Q1 2026 global revenue for Mounjaro will be at least $7.1 billion, according to the Metaculus prediction community.


Public Figures


Articles on this story



© 2026 Improve the News Foundation. All rights reserved.Version 6.18.0

© 2026 Improve the News Foundation.

All rights reserved.

Version 6.18.0